South Africa

Study shows six-monthly anti-HIV jab could end Aids in South Africa by 2032

By Mia Malan

Africa

The Global Fund will roll out the twice-yearly anti-HIV jab — with or without Pepfar

By Ida Jooste

Politics

US embassy confirms Pepfar projects will restart — despite Trump’s aid ban in SA

By Mia Malan

South Africa

Too little, too late — what a Pepfar waiver can’t do

By Mia Malan

Business Maverick

After the Bell: About 2024 — let me tell you the good news…

By Tim Cohen

Sci-Tech

Viatris launches local ARV production in South Africa: a game changer for HIV treatment accessibility

By Naledi Sikhakhane

Op-eds

South Africa's HIV challenge: progress towards 2030 goals requires urgent action and innovation

By Salim Abdool Karim and Nikita Devnarain for Spotlight

South Africa

A call for urgent action in navigating the complex landscape of long-acting HIV medications

By Francois Venter

Op-eds

How South Africa can help secure immediate, global access to HIV prevention drug lenacapavir

By Tian Johnson, Fatima Hassan, Asia Russell and Sangeeta Shashikant

Maverick Citizen

Talks have started to get the twice-yearly anti-HIV jab registered in SA

By Mia Malan

South Africa

Efficacy of six-monthly HIV prevention jab confirmed in second major study

By Elri Voigt for Spotlight

Maverick Citizen

Almost 40% of the world’s anti-HIV pill users live in South Africa

By Mia Malan, Linda Pretorius and Zano Kunene